As a result, several studies have revealed the increased effectiveness of targeting heterodimeric receptors or simultaneously targeting both the IGF1R and IR as novel anti-cancer therapies compared to targeting IGF1Rs alone [30], [37], [38]. This evidence concerns the gene INSR and cancer.